AstraZeneca (AZN) Stock Rating Reaffirmed by Deutsche Bank

Deutsche Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a report published on Thursday. They currently have a GBX 5,700 ($77.30) price target on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. Investec lifted their price target on AstraZeneca from GBX 4,900 ($66.45) to GBX 5,500 ($74.59) and gave the stock a buy rating in a research report on Monday, November 6th. Citigroup reaffirmed a buy rating and set a GBX 6,000 ($81.37) price target on shares of AstraZeneca in a research report on Wednesday. Barclays set a GBX 6,300 ($85.44) price target on AstraZeneca and gave the stock a buy rating in a research report on Wednesday, September 13th. Berenberg Bank set a GBX 5,800 ($78.65) price target on AstraZeneca and gave the stock a buy rating in a research report on Tuesday, September 19th. Finally, Jefferies Group reaffirmed a hold rating and set a GBX 5,100 ($69.16) price target on shares of AstraZeneca in a research report on Monday, November 6th. Four analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. AstraZeneca currently has an average rating of Hold and a consensus price target of GBX 5,200.82 ($70.53).

AstraZeneca (AZN) remained flat at $GBX 5,132 ($69.60) on Thursday. The company had a trading volume of 1,835,225 shares, compared to its average volume of 1,720,000. The company has a market cap of $64,820.00 and a price-to-earnings ratio of 2,479.23. AstraZeneca has a 1 year low of GBX 4,136.50 ($56.10) and a 1 year high of GBX 5,520 ($74.86).

TRADEMARK VIOLATION NOTICE: This piece was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/13/astrazeneca-azn-stock-rating-reaffirmed-by-deutsche-bank.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit